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Abstract
Background: Both high-sensitivity C-reactive protein (hs-CRP) and spiral computed tomo-
graphy coronary artery calcium score (CCS) are valid markers of cardiovascular risk. It is
unknown whether hs-CRP is a marker of atherosclerotic burden or whether it reflects a process
leading to acute coronary events.
Methods and Results: We studied the relation between hs-CRP and CCS in 143 patients
that were candidates for coronary artery bypass grafting (CABG). In our cross-sectional study,
we found no significant association between hs-CRP and CCS in bivariate (p = 0.162) and
multivariate (p = 0.062) analysis, but in patients who did not use statins this association was
positive and significant in bivariate analysis (p = 0.001), and in multivariate analysis this
association was negative and significant (p = 0.008).
Conclusions: High-sensitivity CRP was not correlated with CCS. The relation between CRP
and clinical events might not be related to atherosclerotic burden. Measures of inflammation,
such as hs-CRP, and indices of atherosclerosis, such as CCS, are likely to provide distinct
information regarding cardiovascular risk. (Cardiol J 2008, 15: 431–436)
Key words: coronary calcification, inflammation, risk factors, multislice spiral
computed tomography, high-sensitivity C-reactive protein
Introduction
A great deal of evidence suggests that inflam-
mation plays a major role in the development of
atherosclerosis and its clinical manifestations [1, 2].
In some studies, plasma levels of inflammatory
markers, particularly high-sensitivity C-reactive
protein (hs-CRP), predict myocardial infarction and
cardiovascular death [3–8]. However, hs-CRP is
associated with many established risk factors inclu-
ding dyslipidemia, cigarette smoking, hypertension,
diabetes and obesity [9–15]. The relation between
hs-CRP and coronary artery disease (CAD) was
positive and significant in some studies [16–18], in
other studies this relation was not significant [17,
19–27] and in others it was negative and significant
[28, 29]. The extent to which hs-CRP levels pre-
dict clinical events depends on the relation of hs-
CRP to the burden of underlying atherosclerosis or
the milieu leading to plaque rupture and thrombo-
sis, and is unknown. Given that hs-CRP levels pre-
dict clinical events, it is of great interest to dissect
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the pathophysiology of this relation. In contrast to
clinical events, an independent association betwe-
en hs-CRP levels and coronary [19–29] or carotid
[27, 30–36] atherosclerosis has not been established
clearly. Coronary artery calcification (CAC), measu-
red by electron beam tomography (EBT) or spiral
computed tomography, might be useful in identify-
ing novel risk factors for coronary atherosclerosis
in asymptomatic subjects. The amount of CAC at
EBT is correlated with the burden of atherosclerosis
at both autopsy and coronary angiography [37, 38]
and studies suggest that CAC is a predictor of cli-
nical CAD events in both symptomatic [39] and
asymptomatic [40, 41] subjects. Studies of CAC
might permit differentiation of factors associated
with coronary atherosclerosis from those related to
plaque rupture or thrombosis.
Studies of hs-CRP and CAC in healthy subjects
have produced conflicting results. Whereas some
have found no association between hs-CRP and
CAC [17–29], others have reported a weak relation
[16–18]. It is unclear whether these conflicting re-
ports reflect the limitations of study design and ana-
lysis or real differences in the pathophysiology of
CAC, a measure of coronary atherosclerotic burden,
and elevated hs-CRP, a marker of inflammation.
Some support the concept that coronary calcium
scores (CCS) and plasma hs-CRP levels might pro-
vide independent and complementary information
regarding the risk of cardiovascular events [22, 42].
We examined the association between plasma
hs-CRP and CCS in patients that were candidates
for coronary artery bypass grafting (CABG). In pre-
vious studies, the subjects of studies were suspec-
ted to have CAD without any documentation, but
in our study we selected patients who had CAD do-
cumented by selective coronary artery angiography.
Methods
Study population
The study population consisted of 143 patients
with coronary artery disease that were admitted to
the Shaheed Rajaei Cardiovascular Center, an acade-
mic tertiary referral center, between December 2006
and March 2007 for CABG. When the patients were
admitted to our centre for CABG, their history was
taken and physical examinations were carried out.
Exclusion criteria were:
— history of myocardial infarction or unstable an-
gina during previous month;
— history of aortic valve replacement or mitral va-
lve replacement;
— history of CABG or coronary stenting.
All study participants gave written informed
consent. The protocol was approved by the Rese-
arch Committee at the Iran University of Medical
Sciences, Tehran. Age, cardiac risk factors inclu-
ding hypertension, dyslipidemia, diabetes mellitus,
family history of coronary disease, smoking status
and drug history were determined by interview
(self-reported), and body mass index (BMI) by exa-
mination.
Biochemical data determination
Blood sampling was done for lipid profile, cre-
atinine [43–45] and hs-CRP, and the blood samples
were frozen at –70oC for four months. The hs-CRP
was done using commercial kits (Pars Azmun Co.),
by latex immunoturbid assay (detection limit was
0.1 to 10 mg/L and coefficient variation was 1%) and
by a single laboratory technician blinded to all cli-
nical and radiological data.
Coronary calcium score determination
Coronary calcium scoring was done by 10-sli-
ce spiral computed tomography scan (Siemens So-
matom Sensation 10). The calcium score of coro-
nary artery was expressed according to the work
of Agatston and colleagues [46]. A total CAC score
was determined from the sum of the individual sco-
res of the four major epicardial coronary arteries.
A single radiologist, blinded to all clinical and sero-
logic data, interpreted all scans.
Statistical analysis
The data were analyzed by SPSS 15 softwa-
re and reported as mean ± standard deviation
(SD) if continuous, and as proportions if catego-
rical. Because some variables did not have nor-
mal distribution, we transformed them to loga-
rithmic values for normalization of data, and be-
cause some patients had CCS=0, log (CCS+1)
was substituted. Firstly, we assessed the asso-
ciation between coronary calcium score log
(CCS+1) and log (hs-CRP) overall by Pearson
correlation coefficient and then in the presence
of age, sex, any risk factors and any drugs use
by this method. Because almost all patients used
aspirin and beta-blockers, and a very small per-
centage of patients used calcium channel bloc-
kers or gemfibrozil, we did not include these
variables in our analysis. Secondly, we assessed
this correlation by multivariable linear regres-
sion (enter mode) overall, and then, in accordan-
ce with statin usage, we entered age, BMI, drug
history, all risk factors, lipid profile and creati-
nine in multivariable analysis.
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Results
Table 1 shows the demographic characteristics,
hs-CRP levels and CCS scores in the sample (n =
= 143). Distribution of CCS is presented in Table 2.
Bivariate analysis of the correlation of hs-CRP
and CCS in all patients and subgroups are presen-
ted in Table 3. This correlation was not significant
overall (r = –0.118, p = 0.162) but was significant
in 60–69-year-old patients (r = 0.327, p = 0.031),
and these correlations were moderate and signifi-
cant in patients that did not use statins (r = 0.442,
p = 0.001). In other subgroups, this correlation was
not significant. Factors associated with CCS when
hs-CRP was not included in fully adjusted, multi-
variable linear regressions are shown in Table 4.
Age, male sex and family history of coronary arte-
ry disease were positive predictors of CCS.
Factors associated with CCS when hs-CRP was
included in fully adjusted, multivariable linear re-
gressions are shown in Table 5. Age was the only
predictor of CCS in the presence of hs-CRP; sex and
family history of coronary artery disease were not
predictors of CCS after adjustment for hs-CRP
levels. Because, in bivariate analysis, the associa-
tion of hs-CRP and CCS was significant in patients
who did not use statins, we analyzed this asso-
ciation in these patients using fully adjusted,
Table 1. Characteristics of the study sample.
Age (years) 57.7 ± 9.4
< 50 18.2
50–59 39.2
60–69 30.8
> 70 11.9
Body mass index [kg/m2] 27.2 ± 3.5
< 24.99 29.4
25–29.99 49
> 30 21.6
Triglycerides [mmol/L] 1.73 ± 0.88
Cholesterol [mmol/L] 4.46 ± 1.27
LDL cholesterol [mmol/L] 4.43 ± 0.81
HDL cholesterol [mmol/L] 1.06 ± 0.98
Creatinine [mmol/L] 121.1 ± 84
hs-CRP [mg/L] 2.89 ± 3.43
Coronary calcium score 366.4 ± 586.7
Male 74.1
Hypertension 32.2
Dyslipidemia 45.5
Diabetes mellitus 32.9
Cigarette smoking 35
FH 14
ACEI/ARB 51.7
Statins 62.2
*Values are mean ±SD, or percent; LDL — low density lipoprotein,
HDL — high-density lipoprotein, hs-CRP — high sensitive C-reactive
protein, FH — family history of coronary artery disease, ACEI/ARB
— angiotensin converting enzyme inhibitors/angiotensin receptor
blockers
Table 2. Percentiles of coronary calcium score (CCS) in the sample.
Percentiles 10 20 30 40 50 60 70 80 90
CCS 3.1 15.9 41.5 85.3 124.5 198.7 399.2 646.6 1107.0
Table 3. Correlation of log (hs-CRP) and log
(CCS+1) in all cases and subgroups.
Group r p
Male 0.122 0.213
Female 0.037 0.828
Hypertension (+) 0.144 0.339
Hypertension (–) 0.118 0.248
Dyslipidemia (+) 0.091 0.469
Dyslipidemia (–) 0.136 0.236
Diabetes mellitus (+) 0.176 0.236
Diabetes mellitus (–) 0.096 0.353
FH (+) 0.101 0.673
FH (–) 0.101 0.267
Cigarette smoking (+) 0.144 0.318
Cigarette smoking (–) 0.110 0.296
ACEI/ARB (+) 0.091 0.442
ACEI/ARB (–) 0.132 0.281
Statin (+) 0.006 0.958
Statin (–) 0.442 0.001
Age (years)
< 50 0.140 0.944
50–59 0.110 0.420
60–69 0.327 0.031
> 70 0.333 0.192
Body mass index [kg/m2]
< 24.99 0.100 0.528
25–29.99 0.080 0.632
> 30 0.323 0.081
All cases –0.118 0.162
(+) indicates the presence of the condition and (–) indicates the
absence of the condition; FH — family history of coronary artery
disease, ACEI/ARB — angiotensin-converting enzyme inhibitors/
/angiotensin receptor blockers
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multivariable linear regression. Table 6 shows this
analysis. Male sex and family history of coronary
artery disease were positive predictors of CCS, and
hs-CRP was a negative predictor of CCS (p = 0.008)
in patients who did not use statins.
Discussion
Traditionally, the risk of a clinical coronary
event reflects the burden of underlying coronary
atherosclerosis, factors that lead to plaque rupture
and factors that promote thrombus formation. Co-
ronary artery calcification is strongly associated
with total plaque burden, as proven in histopatho-
logical studies. The amount of CAC at EBT is cor-
related with the burden of atherosclerosis at both
autopsy and coronary angiography [37, 38] and pre-
liminary studies suggest that CAC is a predictor of
clinical CAD events in both symptomatic [39] and
asymptomatic subjects [40, 41]. Studies of CAC
might permit the differentiation of factors associa-
ted with coronary atherosclerosis from those rela-
ting to plaque rupture or thrombosis. CCS, measu-
red by spiral computed tomography, might be use-
ful for exploring the relation of risk factors with
Table 4. Multivariate analysis of factors associated
with coronary calcium score when high-sensitivity
C-reactive protein (hs-CRP) is not included in
analysis.
B SD P
(Constant) 1.173 1.323 0.377
Age 0.034 0.008 0.000
Sex –0.409 0.191 0.035
Hypertension 0.304 0.177 0.089
Dyslipidemia 0.019 0.163 0.909
Diabetes mellitus 0.121 0.165 0.464
FH 0.470 0.212 0.028
Cigarette smoking 0.058 0.172 0.735
ACEI/ARB –0.069 0.153 0.651
Statin –0.146 0.157 0.355
LDL 0.000 0.003 0.859
Log HDL 0.138 0.184 0.455
Log TG –0.182 0.159 0.257
Log CR –0.134 0.252 0.598
Body mass index –0.014 0.021 0.514
Results of linear regression [log (CCS+1) as the dependent variable]
presented when log hs-CRP is not included in the analysis, as the
change log (CCS+1) for a specific change in risk factor. The model
was adjusted for the following variables; age, sex, history of hyperten-
sion, history of dyslipidemia, diabetes mellitus, family history of coro-
nary artery disease (FH), smoking, use of the following medications:
statins, angiotensin converting enzyme inhibitors/angiotensin recep-
tor blockers (ACEI/ARB), LDL (log LDL), HDL (log HDL), TG (log TG),
CR (log CR), body mass index; CR — creatinine; TG — triglycerides
Table 5. Multivariable analysis of factors associated
with coronary calcium score when high-sensitivity
C-reactive protein (hs-CRP) is included in
analysis.
B SD P
(Constant) 1.046 1.312 0.427
Age 0.037 0.008 0.000
Sex –0.343 0.193 0.078
Hypertension 0.293 0.176 0.099
Dyslipidemia –0.005 0.161 0.977
Diabetes mellitus 0.141 0.164 0.392
FH 0.395 0.213 0.067
Cigarette smoking 0.068 0.170 0.688
ACEI/ARB –0.032 0.153 0.834
Statin –0.204 0.158 0.200
LDL 0.001 0.003 0.657
Log HDL 0.089 0.184 0.630
Log TG –0.169 0.158 0.288
Log CR –0.063 0.253 0.802
Body mass index –0.013 0.021 0.542
Log hs-CRP –0.115 0.061 0.062
Results of linear regression [log (CCS+1) as the dependent variable]
presented when log hs-CRP is included in analysis as the change log
(CCS+1) for a specific change in risk factor. The model was adjusted
for the following variables; age, sex, history of hypertension, history
of dyslipidemia, diabetes mellitus, family history of coronary artery
disease (FH), smoking, use of the following medications: statins,
angiotensin converting enzyme inhibitors/angiotensin receptor bloc-
kers (ACEI/ARB), LDL (log LDL), HDL (log HDL), TG (log TG), CR (log
CR), body mass index and hs-CRP (log hs-CRP); CR — creatinine;
TG — triglycerides
Table 6. Multivariable analysis of factors associa-
ted with coronary calcium score high-sensitivity
C-reactive protein (hs-CRP) in patients that did
not use statins.
B SD P
(Constant) 3.774 1.682 0.031
Age 0.021 0.012 0.088
Sex –0.653 0.262 0.017
Hypertension 0.318 0.259 0.227
Dyslipidemia 0.086 0.243 0.724
Diabetes mellitus 0.250 0.226 0.276
FH 0.682 0.318 0.038
Cigarette smoking –0.346 0.275 0.215
ACEI/ARB 0.191 0.231 0.414
LDL 0.004 0.004 0.294
Log HDL 0.188 0.219 0.396
Log TG –0.261 0.241 0.285
Log CR –0.531 0.292 0.077
Body mass index –0.068 0.037 0.077
Log hs-CRP –0.278 0.100 0.008
Results of linear regression [log (CCS+1) as the dependent variable]
are presented in patients who did not use statins, as the change log
(CCS+1) for a specific change in risk factor. The model was adjusted
for the following variables; age, sex, history of hypertension, history
of dyslipidemia, diabetes mellitus, family history of coronary artery
disease (FH), smoking, use of the following medications: statins,
angiotensin converting enzyme inhibitors/angiotensin receptor bloc-
kers (ACEI/ARB), LDL (log LDL), HDL (log HDL), TG (log TG), CR (log
CR), body mass index and hs-CRP (log hs-CRP); CR — creatinine;
TG — triglycerides
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coronary atherosclerosis. We found no evidence of
a positive association between hs-CRP and calcium
scores. Indeed, if anything, these data suggest an
inverse relationship between hs-CRP levels and
coronary calcium in patients who did not use sta-
tins. Nonetheless, we believe the lack of a positive
association between hs-CRP and coronary calcium
score deserves careful consideration. The lack of
correlation in the current data between spiral com-
puted tomography CCS and hs-CRP suggests that
calcification may be less likely to reflect inflamma-
tion per se; spiral computed tomography detected
calcification may predominantly be a marker for ma-
ture, and hence stable, atherosclerotic plaque, and
thus only be an indirect marker for the presence of
uncalcified rupture-prone lesions, which may be
more likely markers for future cardiac events. Ho-
wever, a correlation between soft, noncalcified pla-
que and hs-CRP has not been confirmed [24].
Deposition of calcium in atherosclerotic lesions
has been shown to be an active process analogous
to the formation of bone spicules [47]. Thus, coro-
nary calcification may not merely be a direct con-
sequence of atherogenesis but may depend upon the
presence of specific determinants independent of
the central processes involved in plaque formation.
Our finding supports the concept that hs-CRP le-
vels might not be related to atherosclerosis but may
be a marker of plaque rupture and thrombosis. The-
refore, hs-CRP might not be useful in identifying
the underlying mechanisms of atherosclerosis ini-
tiation or progression.
We used a validated commercial assay for the
measurement of hs-CRP, but variability in commer-
cial assays may limit the validity of these data. We
used CCS as a surrogate for coronary atheroscle-
rotic plaque burden based on the well-established
relationship between CCS and the extent of histo-
logical plaque [37]. However, atherosclerosis in
vascular beds other than the coronary arteries co-
uld also contribute to the level of hs-CRP [48].
Conclusions
This study demonstrates that hs-CRP is unre-
lated to the presence and severity of clinical calci-
fied atherosclerosis, and suggests that serologic
inflammatory markers are principally a measure of
the atheroinflammatory disease process and are not
an index of the extent of coronary atherosclerotic
plaque. Because CCS and hs-CRP are associated
with risk of subsequent cardiovascular events, the-
se two measures may be complementary rather
than competitive for risk prediction.
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